dc.contributor.author | Chalabianloo, Fatemeh | |
dc.contributor.author | Høiseth, Gudrun | |
dc.contributor.author | Vold, Jørn Henrik | |
dc.contributor.author | Johansson, Kjell Arne | |
dc.contributor.author | Kringen, Marianne K. | |
dc.contributor.author | Dalgard, Olav | |
dc.contributor.author | Ohldieck, Christian | |
dc.contributor.author | Druckrey-Fiskaaen, Karl Trygve | |
dc.contributor.author | Aas, Christer Frode | |
dc.contributor.author | Løberg, Else-Marie | |
dc.contributor.author | Bramness, Jørgen Gustav | |
dc.contributor.author | Fadnes, Lars T. | |
dc.date.accessioned | 2022-08-03T12:53:45Z | |
dc.date.available | 2022-08-03T12:53:45Z | |
dc.date.created | 2022-05-15T17:18:52Z | |
dc.date.issued | 2023 | |
dc.identifier.issn | 1055-0887 | |
dc.identifier.uri | https://hdl.handle.net/11250/3009989 | |
dc.description.abstract | Background: There is limited knowledge on the causes of large variations in serum methadone concentrations and dose requirements.
Objectives: We investigated the impact of the degree of liver fibrosis on dose-adjusted steady-state serum methadone concentrations.
Methods: We assessed the clinical and laboratory data of 155 Norwegian patients with opioid use disorder undergoing methadone maintenance treatment in outpatient clinics in the period 2016–2020. A possible association between the degree of liver fibrosis and dose-adjusted serum methadone concentration was explored using a linear mixed-model analysis.
Results: When adjusted for age, gender, body mass index, and genotypes of CYP2B6 and CYP3A5, the concentration-to-dose ratio of methadone did not increase among the participants with liver fibrosis (Coefficient: 0.70; 95% CI: −2.16, 3.57; P: 0.631), even among those with advanced cirrhosis (−0.50; −4.59, 3.59; 0.810).
Conclusions: Although no correlation was found between the degree of liver stiffness and dose-adjusted serum methadone concentration, close clinical monitoring should be considered, especially among patients with advanced cirrhosis. Still, serum methadone measurements can be considered a supplement to clinical assessments, taking into account intra-individual variations. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Taylor & Francis | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2022 The Author(s) | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.1080/10550887.2022.2057140 | |
dc.identifier.cristin | 2024705 | |
dc.source.journal | Journal of Addictive Diseases | en_US |
dc.source.pagenumber | 53-63 | |
dc.relation.project | Helse Vest RHF: F-11328 - 912126 | en_US |
dc.identifier.citation | Journal of Addictive Diseases. 2023, 41 (1), 53-63. | en_US |
dc.source.volume | 41 | |
dc.source.issue | 1 | |